Nirmatrelvir and ritonavir. Information for patients
Fecha
2022Número de documento
PAHO/HSS/MT/COVID-19/22-0035
Metadatos
Mostrar el registro completo del ítemOtros idiomas
Resumen
The Pan American Health Organization presents this brochure in order to inform patients and the general public about the combination of nirmatrelvir with ritonavir. This treatment, which requires a prescription, is indicated for mild to moderate cases in people with a positive confirmatory test who are at high risk of progression to severe or critical illness and hospitalization.
Colecciones
Esta leyenda debe conservarse, junto con la URL original del artículo.Attribution-NonCommercial-ShareAlike 3.0 IGO
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Rosa, Sandro G. Viveiros; Santos, Wilson C. (2020)[ABSTRACT]. The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were ...
-
Mello, Vinícius de; Pereira, Vinícius de Paula; Rodrigues, João Paulo Vilela; Penteado, Suelem Tavares da Silva; Pereira, Leonardo Régis Leira; Varallo, Fabiana Rossi (2022)[RESUMO]. Objetivo. Identificar eventos adversos no sistema nervoso central (SNC) potencialmente associados ao uso de medicamentos para profilaxia ou tratamento da COVID-19, bem como caracterizar os indivíduos acometidos. ...
-
Pan American Health Organization; Health Systems and Services (HSS) (PAHOUnited StatesWashington, D.C., 2022)The purpose of this publication is to make health professionals aware of the potential benefits and risks of the combination of nirmatrelvir with ritonavir in the treatment of COVID-19, since, compared to other treatments, ...